Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANDHI benralizumab in severe uncontrolled asthma
2017-001040-35Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing Benralizumab with Placebo (2 arms). Primary endpoint: Annualized asthma exacerbation rate. Started Jun 2017; status: completed.
02
Drugs
benralizumab
03
Conditions
asthma
Beyond the preview
Go deeper on 2017-001040-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001040-35.